Zepbound is a GLP-1 weight-loss treatment key to a wave of obesity drug adoption and market disruption.
Global markets face a sustained AI-driven rally that has drawn in banks, chipmakers, and tech giants. Q2 earnings show a windfall for underwriting and trading, while investors watch chip prices and capex, with earnings momentum remaining a focal point for the AI trade.
Weight-loss GLP-1 drugs are expanding beyond injections to pills in the US, UK and UAE. Major manufacturers report rising uptake and ongoing development, with Medicare and NHS access shaping pace and affordability. Private prescriptions and new formulations are widening access while competition accelerates.
Whey protein, once a byproduct of cheese making, has become a hot commodity as demand for protein grows amid weight‑loss drug uptake and broader consumer interest. Inventories are falling and prices have risen, while producers race to expand capacity to meet rising demand.
A new weight‑loss pill version of semaglutide has launched in the UK for private prescriptions, offering an alternative to injections. The tablet requires strict dosing and a fasting routine and is not yet NHS‑funded. Several outlets warn about counterfeit pills as access broadens.
The wedding dress market is shifting as GLP-1 weight loss drugs become common among engaged couples. Designers report earlier fittings, changed guarantees, and rising alterations costs. Brides worry about weight loss before weddings, while sales staff push early purchases and flexible guarantees.
Novo Nordisk has filed a US lawsuit accusing Eli Lilly of false advertising over weight-loss and diabetes drugs, claiming Lilly used outdated trial data to claim superiority. Lilly argues its ads rely on SURMOUNT-5 results and defends its campaigns. The case highlights a race for market share in GLP-1 obesity and diabetes treatments, with potential damages and corrective ads on the table.